Stocks and Investing Stocks and Investing
Mon, August 14, 2023

Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $54 on, Aug 14th, 2023


Published on 2024-10-28 05:52:43 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $54 on, Aug 14th, 2023.

Raghuram has made no other calls on URGN in the last 4 months.



There are 2 other peers that have a rating on URGN. Out of the 2 peers that are also analyzing URGN, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Choi of "Goldman Sachs" Maintained at Hold with Increased Target to $18 on, Monday, July 31st, 2023


This is the rating of the analyst that currently disagrees with Raghuram


  • Leland Gershell of "Oppenheimer" Reiterated at Buy and Held Target at $22 on, Monday, May 15th, 2023
Contributing Sources